---
schema_version: "secwatch.filing_event.v1"
accession: "0001438133-24-000158"
form_type: "8-K"
ticker: "TNDM"
cik: "0001438133"
company_name: "TANDEM DIABETES CARE INC"
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T03:51:56.624656+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tandem and Dexcom amend agreements to integrate Sigi pump with G7 CGM for five years

## Summary
- On May 22, 2024, Tandem and Dexcom entered into two amended and restated agreements.
- The Development Agreement covers integration of Tandem's Sigi insulin pump with Dexcom's G7 CGM.
- Both agreements extend the term to five years and amend definitions and commercial terms.
- The Commercialization Agreement addresses the sale and support of the integrated systems.
- Original agreements were signed November 2020; new deals update device scope and conditions.

## SEC filing metadata
- accession: 0001438133-24-000158
- form_type: 8-K
- ticker: TNDM
- cik: 0001438133
- company_name: TANDEM DIABETES CARE INC
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438133/000143813324000158/0001438133-24-000158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438133/000143813324000158/tndm-20240522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438133-24-000158
- JSON: https://secwatch.observer/filing/0001438133-24-000158.json
- Plain text: https://secwatch.observer/filing/0001438133-24-000158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.